Zynerba Pharmaceuticals

Zynerba Pharmaceuticals carries a Neutral rating with three-out-of-five conviction, anchored by a composite score of 40. Regulatory is the strongest pillar, scoring just below 50 through a neutral jurisdiction posture and a high enforcement subscore reflecting no recorded enforcement hits. Market ranks at 40 despite unavailable quotation data, while fundamentals sit in the upper 30s as weak cash-runway and market-cap tiers offset stronger operating-margin scoring. Editorial contributes the least at 30 because CIN newsroom coverage contains no recent news or brief activity. The resulting profile supports neither a premium rating nor an outright bearish stance.

Licensed fundamentals data show no year-over-year revenue growth, with both gross and operating margins reported at zero. EBITDA remains negative at approximately $38.6 million, while the supplied net-income figure is flat. Market capitalization stands near $70.1 million, and the cash-burn ratio is roughly 0.55. Those figures align with the stable financial-condition designation but leave the fundamentals pillar constrained by a cash-runway subscore of 15 and a market-cap subscore in the mid-30s. Primary regulatory filings show no recorded events during either the past 90 days or the broader 180-day period, while no latest filing date is available. That absence suppresses the cadence subscore to 25 even as the clean enforcement record delivers an 80 subscore. Institutional pricing feeds provide no current quote, limiting confirmation from market behavior.

The clearest forward catalyst is renewed primary regulatory filing activity, directly tied to the regulatory pillar that already leads the framework. A dated, substantive filing would strengthen cadence visibility and add measurable progress to the jurisdiction and enforcement foundation. Consistent filings could also create fresh inputs for CIN newsroom coverage, improving the weakest pillar without relying on unavailable pricing data. The single most important signal to watch is the appearance of a new substantive primary regulatory filing that restores a verifiable reporting cadence.